The shadow of generic rivalry has consistently loomed over copyright’s iconic drug, Sildenafil, raising questions about the prospects of related pharmaceutical investments. While first times saw substantial returns, the patent expiration has created the door for less expensive copies, potentially diminishing revenue and presenting a genuine risk